Navigation Links
UNC study shows potential to revive abandoned cancer drug by nanoparticle drug delivery

CHAPEL HILL, N.C. - Current nanomedicine research has focused on the delivery of established and novel therapeutics. But a UNC team is taking a different approach. They developed nanoparticle carriers to successfully deliver therapeutic doses of a cancer drug that had previously failed clinical development due to pharmacologic challenges. They report their proof of principle findings in the April 30, 2012 early online edition of Proceedings of the National Academy of Sciences.

Wortmannin is a drug that was highly promising as a cancer drug, but its successful preclinical studies did not translate into clinical efficacy because of challenges such as high toxicity, low stability and low solubility (unable to be dissolved in blood).

Andrew Z. Wang, MD, study senior author, says, "Drug development is a difficult and expensive process. For a cancer drug to make it to clinical use, it not only has to be effective against cancer cells, but also needs to have low toxicity, good stability and good solubility. Many promising drugs such as wortmannin failed clinical development because they failed one or more of these requirements. Nanoparticle drug delivery is a breakthrough technology and has the ability to overcome these limitations. Our study is a proof of principle to demonstrate that nanoparticles can renew the clinical potential of many of these 'abandoned' and 'forgotten' drugs.

"We found that the nanoparticle formulation of wortmannin decreased toxicity and increased stability, solubility and effectiveness. Additionally, nanoparticle wortmannin can improve the efficacy of radiotherapy dramatically and is more effective than the most commonly utilized chemotherapeutics. " Wang is a member of UNC Lineberger Comprehensive Cancer Center.

Wang explains, "Most research has focused on established drugs. However, there is a large number of these 'forgotten' drugs that can be revived and re-evaluated using nanoparticle drug delivery. These drugs can provide new targets and offer new strategies that previously didn't exist."

The team will now focus on further development of the nanoparticle wortmannin as well as look into developing nanoparticle formulation of other abandoned drugs.

Contact: Dianne G. Shaw
University of North Carolina School of Medicine

Related medicine news :

1. Clues to Slacker Behavior Found in Brain, Study Says
2. Women More Likely to Survive Melanoma Than Men: Study
3. Study finds that patient education videos viewed before an operation may benefit patients
4. Interpreting the Avastin-Lucentis study for persons with macular degeneration
5. Study Downplays Risk of CT Scans
6. Seniors Undertreated for Asthma, and Many Skip Inhalers: Study
7. Tasers Can Trigger Fatal Heart Trouble, Study Says
8. New study identifies how information technology is used to solve global health challenges
9. Here Are the Women Who Need Mammograms in Their 40s: Study
10. Many Asthmatic Kids Harmed by Secondhand Smoke: Study
11. Tasers Can Trigger Fatal Heart Trouble: Study
Post Your Comments:
Related Image:
UNC study shows potential to revive abandoned cancer drug by nanoparticle drug delivery
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... "FCPX editors ... customizable inside of Final Cut Pro X," said Christina Austin - CEO of Pixel ... style. Final Cut Pro X users can now reveal the media of ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer ... they remain in the eye of the beholder, according to experts who offered insights ... American Journal of Managed Care. For the full issue, click here . , ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016   Bay Area Lyme Foundation ... Dean Center for Tick Borne Illness , Harvard ... MIT Hacking Medicine, University of California, Berkeley, and ... the five finalists of Lyme Innovation , ... than 100 scientists, clinicians, researchers, entrepreneurs, and investors ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
Breaking Medicine Technology: